Quantum Genomics — Report Publication Announcement 2014

Nov 5, 2014

Massy - Le 5 novembre 2014

Publication d'une note d'analyse financière indépendante rédigée par Aurgalys

Quantum Genomics (Alternext - FR0011648971 - ALQGC), société biopharmaceutique dont la mission est de développer de nouvelles thérapies pour des besoins médicaux non satisfaits dans le domaine des maladies cardiovasculaires, annonce que le bureau d'analyse financière Aurgalys, spécialisé dans les sciences de la vie, a initié la couverture de l'entreprise.

Leur première étude, intitulée « Quantum Genomics could revolutionize the hypertension market » (Quantum Genomics pourrait révolutionner le marché de l'hypertension artérielle), est disponible sur le site internet de Quantum Genomics (wwww.quantum-genomics.com), rubrique Investisseurs, onglet Analyses financières, ainsi que sur le site internet d'Aurgalys (www.aurgalys.com).

Cliquez sur la note d'analyse financière pour la consulter :

	ALTERNATI ALGSC IFRODITABBITED
Share Price: 65.77 DA OF MANAGEMENT APT. 2014).	Quantum Genomics could revolutionize the hypertension market
Estimated price: 69.72	Quantum Genomics is an early stage pharmaceutical company, dedicated to the development of a new remeration of drugs for cardoverniar dimens. The company's Brain Aminopeatidase A. inhibitor (8APArt) technology, first-in-class drugs, could address
Sales and more 19 for 14 11 19 per cent	a 51008 market, Deartham Genomics' lead compound, OGC003. is about to enter those to clears station and could treat
27.8 Market Cap (FM)	raticizer hypersenten, a condition affecting 10-15% of all breachamine autisms (100-150 million patients worldwide). We are initiating coverage on Quantum Genomics with a value per
15 Reterated Cash Foatfall HW	share of 49.72, reflecting both the market potential of OGC001 as well as the risk associated with a drug that seeds to
ai d Estimated market can œ	deconomate its efficacy in human subjects. 040001 cauld serve the interests of both patients and the
Rocker of Stars (B) $\overline{1}$	educer annuling industry Quantum Generals: is a pharmamutical company whose lead since. OSCODE, is an early stage drug candidate. OSCODE is being evaluated for
*** Estimated artist RT	the treatment of restaure hypertension. Depote numerous sings currently publishe to control high blood pressure. \$0-15% of huperbensive aptients. do not respond to these transments. OGCRES is a finalizable's sing-
Islama 3 months FSM PERMIT	turgeting the bruin Benticulingtenerate-Abbesterane System that has abount promising results in primal models. Should OGGBES reach the market. It would provide a thempeutic solution for the treatment of hypertension.
Free Plyint IKIN	that course placed Muslim deaths would side. OGCODI also nearesteria a strong financing candidate for large
Dividend Forecast 12 m dia ff	phermannical groups looking to augment their primary care product portfolio. With optents expired or shout to expire in the coming want. intercation drum have became a necessity for these companies solding to: maintain their market chare in the field of hypertension and continuous-dan бизил.
	Durcher Grounds Intends to Liense OCCED after simplice Plane Sa. results in hupertension. Upfront and milestone assuments would contribute in the short/inid-term to finance other drugs in development, which are currently in arguining market.
	Valuation of Quantum Genomics

A propos de Quantum Genomics

Quantum Genomics est une société biopharmaceutique dont la mission est de développer de nouvelles thérapies pour des besoins médicaux non satisfaits dans le domaine des maladies cardiovasculaires, notamment l'hypertension artérielle et l'insuffisance cardiaque.

Quantum Genomics développe une nouvelle approche thérapeutique basée sur l'inhibition de l'aminopeptidase A au niveau cérébral (BAPAI - Brain Aminopeptidase A Inhibition), résultat de plus de vingt années de recherche académique au sein des laboratoires du Collège de France, de l'INSERM et du CNRS.

Quantum Genomics est cotée sur le marché Alternext à Paris (code ISIN : FR0011648971 - mnémo : ALQGC).

Contacts

Quantum Genomics	Quantum Genomics	ACTUS
Lionel Ségard	Marc Karako	Jean-Michel Marmillon
Président-Directeur Général	Vice-président Finance - Relation investisseurs	Relations Presse
01 60 13 76 80	01 60 13 76 84	01 53 67 07 80
	marc.karako@quantum-genomics.com	jmmarmillon@actus.fr